Changes in Tears Monocyte Chemoattractant Protein-1 Level After External Dacryocystorhinostomy in Primary Acquired Nasolacrimal Duct Obstruction

Background: The authors aimed to define tears monocyte chemoattractant protein-1 (MCP-1) changes after external dacryocystorhinostomy surgery. Materials and Methods: Tears samples were collected with a Schirmer strip and stored in Eppendorf tubes at −80°C. At the end of the study, the papers were cut into small pieces and incubated with phosphate-buffered saline solution. Monocyte chemoattractant protein-1 levels were determined by using an enzyme-linked immunosorbent assays kit. Results: The MCP-1 levels were 498.66±101.35, 576.40±149.78, 422.53±85.94, and 436.96±81.38 ng/L before surgery, in the first week, the first, and third months after surgery, respectively. Its level significantly increased in the first week compared with the preoperative level (P<0.001). There was a prominent decrease in the postoperative first month (P<0.001). In the third postoperative month, the mean MCP-1 level was not significantly increased compared with the postoperative first month (P=0.196). Conclusion: The tears MCP-1 level was significantly decreased after external dacryocystorhinostomy surgery.

[1]  Yizhi Liu,et al.  The Key Role of VEGF in the Cross Talk between Pterygium and Dry Eye and Its Clinical Significance , 2020, Ophthalmic Research.

[2]  I. Kaur,et al.  Alteration of Tear Cytokine Expressions in Primary Acquired Nasolacrimal Duct Obstruction – Potential Insights into the Etiopathogenesis , 2020, Current eye research.

[3]  L. Mawn,et al.  A Comparison of Endonasal Dacryocystorhinostomy and External Dacryocystorhinostomy: A Report by the American Academy of Ophthalmology. , 2019, Ophthalmology.

[4]  M. Ali,et al.  Etiopathogenesis of Primary Acquired Nasolacrimal Duct Obstruction: What We Know and What We Need to Know. , 2019, Ophthalmic plastic and reconstructive surgery.

[5]  Jian Yin,et al.  Hyperprolactinemia is associated with a high prevalence of serum autoantibodies, high levels of inflammatory cytokines and an abnormal distribution of peripheral B-cell subsets , 2019, Endocrine.

[6]  S. Yoshida,et al.  Differential association of elevated inflammatory cytokines with postoperative fibrous proliferation and neovascularization after unsuccessful vitrectomy in eyes with proliferative diabetic retinopathy , 2017, Clinical ophthalmology.

[7]  Yang Liu,et al.  Comparing the Success Rate of Dacryocystorhinostomy With and Without Silicone Intubation: A Trial Sequential Analysis of Randomized Control Trials , 2017, Scientific Reports.

[8]  M. Ali,et al.  Primary Acquired Nasolacrimal Duct Obstruction (PANDO) and Secondary Acquired Lacrimal Duct Obstructions (SALDO) , 2015 .

[9]  E. Eren,et al.  The return of the jedi: comparison of the outcomes of endolaser dacryocystorhinostomy and endonasal dacryocystorhinostomy , 2014, International forum of allergy & rhinology.

[10]  J. K. Lee,et al.  Changes in cytokines in tears after endoscopic endonasal dacryocystorhinostomy for primary acquired nasolacrimal duct obstruction , 2014, Eye.

[11]  A. Yoshida,et al.  Elevated levels of monocyte chemoattractant protein-1 in the aqueous humor after phacoemulsification. , 2012, Investigative ophthalmology & visual science.

[12]  M. Busin,et al.  Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use , 2012, International Ophthalmology.

[13]  C. Sotozono,et al.  Downregulation of monocyte chemoattractant protein 1 expression by prostaglandin E(2) in human ocular surface epithelium. , 2012, Archives of ophthalmology.

[14]  C. Sotozono,et al.  Cytokine storm arising on the ocular surface in a patient with Stevens–Johnson syndrome , 2011, British Journal of Ophthalmology.

[15]  J. Flanagan,et al.  Dacryocystorhinostomy: History, evolution and future directions. , 2011, Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society.

[16]  M. Zapata,et al.  Vitreous levels of interleukine-8 and monocyte chemoattractant protein-1 in macular oedema with branch retinal vein occlusion , 2010, Eye.

[17]  S. Amini,et al.  Monocyte chemoattractant protein-1 (MCP-1): an overview. , 2009, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[18]  F. Sánchez-Jiménez,et al.  Monocyte chemoattractant protein-1: a key mediator in inflammatory processes. , 2009, The international journal of biochemistry & cell biology.

[19]  R. Garadi,et al.  Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: olopatadine hydrochloride versus mometasone furoate monohydrate. , 2007, Allergy and asthma proceedings.

[20]  Joan W. Miller,et al.  Monocyte chemoattractant protein 1 mediates retinal detachment-induced photoreceptor apoptosis , 2007, Proceedings of the National Academy of Sciences.

[21]  H. Lew,et al.  Measurement of pH, Electrolytes and Electrophoretic Studies of Tear Proteins in Tears of Patients with Dacryoliths: A Novel Concept for Dacryoliths , 2004, Ophthalmologica.

[22]  F. Paulsen,et al.  New insights into the pathophysiology of primary acquired dacryostenosis. , 2001, Ophthalmology.

[23]  S. Tseng,et al.  Frequent association of delayed tear clearance in ocular irritation , 1998, The British journal of ophthalmology.

[24]  A. Alm,et al.  The effect of reduced tear drainage on corneal and aqueous concentrations of topically applied fluorescein , 1990, Acta ophthalmologica.